GLP-1 Receptor Agonists in People With HIV: Emerging Evidence and Clinical Implications (On-Demand)

Assessment of Needs

Weight gain and obesity are increasingly prevalent among people with HIV (PWH), and excess adiposity likely contributes to the growing burden of cardiometabolic disease in this population. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have emerged as an effective therapeutic option for weight management, demonstrating substantial weight reduction and associated improvements in cardiometabolic parameters among PWH. This webinar will review the multifactorial contributors to weight gain in individuals receiving antiretroviral therapy (ART) and discuss current evidence-based strategies for managing weight gain in PWH. In addition, the session will address practical clinical challenges, including adverse effects, medication access, and strategies to support patient adherence.

Learning Objectives

On completion of this activity, learners will be able to:

• Describe a multifaceted approach to weight management in PWH
• Describe indications for GLP-1 RA therapy in PWH
• List GLP-1 RA injectable and oral formulations, doses, and adverse reactions
• Manage GLP-1 RA therapy for PWH based on efficacy, safety, and tolerability data
• Registration

Who Should Attend

This webinar is designed for clinical decision makers who are actively involved in HIV care and research, including physicians, physician assistants, nursing professionals, pharmacists, and other health care professionals.

Please note: if you have already participated in the live webinar and have received CME credits, you will not receive additional credits from this activity.

Conflicts of Interest

In the interest of maintaining the independence of its continuing medical education (CME) activities, the International Antiviral Society–USA (IAS–USA) requires all persons with control of educational content (eg, faculty, Scientific Leadership Board, Governance Board, and program planner) to disclose any financial relationships with ineligible companies (previously defined as “commercial interests”) that they have had within the past 24 months. Any real or apparent conflicts of interest of those parties are resolved and mitigated prior to the CME activity being delivered. Individuals who refuse to disclose financial interests may not participate in IAS–USA CME activities. 

The Accreditation Council for Continuing Medical Education (ACCME) defines ineligible companies as “those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.”

IAS–USA has identified and resolved ahead of time any possible conflicts of interest that may influence CME activities with regard to exposition or conclusion. Information about financial relationships with ineligible companies for the presenter and planners/reviewers is below and in the slides prior to the presentation of educational content.

Presenter

Dr Wooten reported no relevant financial relationships with ineligible companies. (Updated March 10, 2026)

Moderator

Dr Bedimo reported receiving research grants awarded to his institution from Merck & Co, Inc; and serving on the scientific advisory boards for Merck & Co, Inc, ViiV Healthcare, Gilead Sciences, Inc, Shionogi, and Janssen Pharmaceuticals. (Updated January 16, 2026)

Planner/Reviewer

Planner/Reviewer 1 reported no relevant financial relationships with ineligible companies. (Updated March 10, 2026)
Planner/Reviewer 2 reported no relevant financial relationships with ineligible companies. (Updated March 10, 2026)

COW Board

The financial relationships of the COW Board can be found here: https://www.iasusa.org/activities/cases-on-the-web/about-cows/cow-webinars-editorial-board/